Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Thrive Precision Health, Inc. (OTC:CNER) Taking Steps To Serve Diabetic Health Sector

China New Energy Group Co

In the world of healthcare investments, the diabetes care market emerges as a compelling arena ripe with opportunities. Several important factors that may attract some investors are driving the sector's growth. At the heart of this surge is the continual development of efficient insulin delivery devices. Technological advancements in healthcare are steering manufacturers to innovate in this crucial area. Projections indicate a substantial uptick in the global diabetes care devices market, from $28,942.1 million in 2022 to an anticipated $42,119.3 million by 2028, reflecting a noteworthy compound annual growth rate (CAGR) of 6.4%. The World Health Organization's recognition of diabetes as a significant global health challenge underscores the urgency for solutions. With over 420 million people affected worldwide, the market demands innovative approaches to address this widespread concern. The insulin market, valued at $21.11 billion in 2022, signifies a substantial financial domain within the broader diabetes care landscape. Predictions hint at its growth to $25 billion by 2030, with North America playing a prominent role, commanding a considerable 38.91% market revenue share in 2022. On a domestic scale, the United States presents a vivid picture of the diabetes epidemic. A staggering 37.3 million Americans are diagnosed with diabetes, while an additional 96 million grapple with pre-diabetes. This prevalence is particularly pronounced in the aging population, where 48.8% of those aged 65 or older face the challenges of this health condition. Looking forward, Global Market Insights anticipates a robust compound annual growth rate of 10% for the diabetes care device market. This projection positions the market to evolve into an $88 billion industry by 2030, offering investors a compelling narrative for potential opportunities in this evolving healthcare landscape. Among the growing landscape of the diabetes care market, one potential hidden gem poised for prominence is Thrive Precision Health, Inc. (OTC: CNER). Thrive Precision Health Inc. is carving its niche as a global diabetes care powerhouse. Trading under the symbol CNER, the company is revitalizing established healthcare clinics specializing in diabetes care. Their unique approach integrates cutting-edge technologies, aiming to create a seamless digital experience for patients worldwide, offering personalized healthcare through the application of AI and quantum biosensors. The company marked a significant milestone on October 5, 2023, by completing a name change to Thrive Precision Health, Inc. This strategic move accompanied the establishment of two wholly-owned subsidiaries, Thrive Testing and Biosafety Inc. and Thrive Precision Health (USA), Inc., signaling a commitment to precision health and a broader global vision. Thrive Precision Health's expansion strategy takes center stage with a recent press release announcing a binding letter of intent to acquire two diabetes clinics in Arizona. The pending acquisition of True Diabetes Neuropathy and Wounds Solutions AZ, LLC, marks the initiation of their strategy to infuse advanced technology into diabetes care. The company is diligently developing a standardized clinical footprint designed for scalability across the nation and internationally. Each clinic is expected to offer a range of services, including wound care, IV therapies, neuropathy treatment, and complementary protocols. With up to 20 IV stations and five wound care treatment rooms per clinic, Thrive envisions generating $5–6 million in total revenues per location, aiming for an impressive 35% EBITDA within each clinic. Guy Zajonc, CEO and Chairman of Thrive Precision Health, is a prime example of the company's leadership, which places a strong emphasis on precision health and personalized medicine. The CEO of True Diabetes, Dr. Jason Mulder, draws attention to the urgent need in Arizona alone, where millions of people suffer from diabetes and there is a severe shortage of treatment resources. In the context of a burgeoning diabetes care market, Thrive Precision Health, Inc. (OTC: CNER) emerges as a compelling player with a vision to transform healthcare delivery. Their strategic acquisitions, commitment to precision health, and innovative approach position them as an intriguing opportunity within a sector poised for significant growth. As the demand for personalized diabetes care rises, CNER stands out as a potential cornerstone in this evolving narrative. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, or assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. Capital Gains Report (CGR) is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR has been retained by ACN LLC to produce and distribute this content related to CGER. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website capitalgainsreport.com All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content. Contact Details Capital Gains Report Mark McKelvie +1 585-301-7700 markrmckelvie@gmail.com Company Website http://CapitalGainsReport.com

November 16, 2023 10:00 AM Eastern Standard Time

PathAI Announces AISight Support of DICOM Standards and Commits to Being a Leader in Integrated Enterprise Image Architecture and Strategy

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced that AISight™ [1] supports rendering DICOM® Visible Light (VL) Whole Slide Microscopy Image files. AISight is a state-of-the-art, interoperable, intelligent case and image management system to assist pathologists in the review of digitized whole slide images (WSIs) with a comprehensive menu of fully embedded AI solutions. The incorporation of modern digital pathology into the DICOM standard was finalized in 2010, allowing organizations to integrate digital pathology into their existing IT systems, providing vendor flexibility, and enabling integrated storage with other imaging modalities (e.g., radiology) in vendor neutral archives (VNAs). DICOM support is a major advancement towards enabling PathAI’s vision of interoperable pathology systems that fit seamlessly into providers current or future enterprise image architecture and strategy. “We’ve been collaborating with many large academic medical centers and health systems over the last year to provide consultative support on digitalization of pathology workflows. In these discussions, one thing is clear. Chief information officers (CIOs) and enterprise imaging architects are pushing for vendors to adopt DICOM to drive imaging interoperability,” said Don O’Neill, SVP of Engineering and IT at PathAI. “PathAI is committed to doing just that and being able to render DICOM image files is the first step in that direction.” As part of its investment into DICOM, PathAI is making a commitment to interoperability and providing solutions that integrate with organizations’ enterprise image management and archive strategy, including through VNAs. PathAI will also launch its DICOMweb API in its next release, which will enable AISight to receive DICOM images from external applications, push images back to VNAs leveraging customer’s DICOMweb API, utilize the DICOM file to supplement or validate image/case data, and enable prefetch to pull historical cases/studies directly from image archives. “By investing into interoperability with enterprise image archives, we’re demonstrating to our customers that we are strategically positioned to provide long term value. No matter where a customer is in the imaging journey, we can help them,” said Andy Beck, MD, PhD, co-founder and chief executive officer of PathAI. To learn more about this integration, visit www.PathAI.com or meet with our team at upcoming conferences including Digital Pathology & AI Congress Europe, London (Booth #30, December 7-8). 1- AISight is for Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of tissue samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to be a rapidly expanding organization of innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 16, 2023 10:00 AM Eastern Standard Time

News Release

Gattaca CEO focused on "rebuilding the business in a really sustainable way"

Gattaca PLC

Gattaca PLC CEO Matthew Wragg speaks to Thomas Warner from Proactive about how the STEM-focused talent solutions company has been performing during a challenging period in the market. Wragg discusses the final results for the year ending in July, highlighting a profit before tax of £2.6 million which marginally exceeded expectations. This positive trajectory comes within the context of a sluggish market, especially in permanent placements, which experienced a slowdown. He expresses optimism about Gattaca's direction, emphasising the internal changes and improvements made over the last 18 months. He noted that the company's focus on STEM skills helps add to its resilience. The conversation also touched on Gattaca's recent decision to relaunch its share buyback. Wragg outlined the rationale behind the move, citing a healthy cash position. Looking ahead, Wragg emphasises the importance of rebuilding corporate memory and fostering a positive environment for success and says he's focused on "rebuilding the business in a really sustainable way." Contact Details Proactive Investors +44 20 7989 0813 uk@proactiveinvestors.com

November 16, 2023 06:20 AM Eastern Standard Time

Video

Cure Alzheimer’s Fund Launches WomenandAlzheimers.org

Alzheimer’s Disease Research Foundation

In honor of National Alzheimer’s Disease Awareness Month, Cure Alzheimer’s Fund announces the launch of WomenandAlzheimers.org, a website dedicated to bringing awareness to the impact of Alzheimer’s on women, providing information on research into understanding sex-based differences and recognizing many of the women who are working toward finding a cure. There are more than 6 million people in the United States—and 50 million people throughout the world—currently living with an Alzheimer’s diagnosis, and experts estimate there may be as many as three times more people living with the disease who have not yet been diagnosed. Both men and women develop Alzheimer’s disease, but two-thirds of all patients are women, and women are frequently the primary caregivers for spouses, partners, parents and others with the disease. “For far too long, science has had a partial view into disease biology because only one sex was included in research studies,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Cure Alzheimer’s Fund has long required researchers to include consideration of potential sex differences in their projects. Understanding why and how Alzheimer’s develops differently in men and women, and the factors that increase resilience or risk, will lead to benefits for all Alzheimer’s patients.” WomenandAlzheimers.org is a resource to learn more about Alzheimer’s disease pathology, signs and symptoms, and the scientific discoveries that are advancing our understanding of the disease. Users can learn about ways to improve brain health, at any age, and read about the women who are working to find a cure, including researchers, Board members, staff members and advocates. About Cure Alzheimer’s FundCure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100% of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, visit https://WomenandAlzheimers.org and https://www.CureAlz.org/ Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website https://WomenandAlzheimers.org

November 15, 2023 05:46 AM Eastern Standard Time

News Release

Nevis Brands announces company is expanding into Michigan with signature brand Major

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to share significant news regarding the company's expansion into Michigan, marking its eighth state in the cannabis market. Nevis Brands has secured an exclusive agreement with Emerald Canning Partners to produce and distribute Major products in the state of Michigan, subject to approval by the Michigan Cannabis Regulatory Agency. Michigan is a strategically important market for Nevis Brands, as it witnessed cannabis sales totaling $2.3 billion in 2022, and it is expected to exceed the $3 billion mark in 2023. This makes Michigan the second territory in the Eastern United States where Nevis is establishing a licensee. Under the agreement with Emerald Canning Partners, Nevis Brands will have exclusive rights to produce and distribute all five flavors of Major, including Sunset Pink Lemonade, Pacific Blue Raspberry, Sacred Grape, Volcanic Orange Mango, and Passionfruit. Major is a dosable 100mg THC beverage known for delivering the effects of cannabis within 10-20 minutes of consumption. This expansion into Michigan represents a significant step for Nevis Brands as it continues to grow its presence in the rapidly evolving cannabis market. With its innovative Major product line and strategic partnerships, Nevis is well-positioned to capitalize on the increasing demand for cannabis products and provide consumers with unique and high-quality options. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

November 14, 2023 01:49 PM Eastern Standard Time

Video

Immunic focusing on business development during Q4

Immunic Inc

Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update. Dr Vitt starts by describing the quarter as a "very eventful and positive quarter for us, dominated by a key message" - positive interim data from its Phase 2 CALLIPER trial of vidofludimus calcium in Progressive Multiple Sclerosis. The financial aspect was also discussed, with the company claiming a cash reserve of $60 million as of the last quarter. The interview highlights the company's efforts to bolster its intellectual property portfolio, citing a notice of allowance from the US Patent Office for the vidofludimous calcium dose strength patent. Dr Vitt discusses the company's focus on business development during the current quarter, expressing confidence in the data and molecules its bringing to discussions with potential partners. He says that "the focus for the company is clearly on the business development side... we [also] continue execution of the vidofludimous MS programs and also prepare a potential phase 2 clinical study for IMU-856." Contact Details Proactive United States +1 347-449-0879 na-editorial@proactiveinvestors.com

November 14, 2023 01:25 PM Eastern Standard Time

Video

MGC Pharmaceuticals reveals strategic objectives for H1 2024

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd CEO and Managing Director Roby Zomer speaks to Thomas Warner from Proactive London following the completion of a share consolidation and capital raise. With these restructuring initiatives completed, Zomer shares his enthusiasm for the future of the plant-based pharmaceutical company and outlines the strategic roadmap for 2024. Zomer emphasises the importance of the recent share consolidation, which involved restructuring the company's capital and introducing new investors aligned with MGC Pharma's long-term vision as a pharmaceutical entity. The CEO highlighted that this move would facilitate the execution of the company's 2024 work plan, presented over the past six months during various roadshows. Acknowledging the impact of the restructuring on existing shareholders, Zomer expresses optimism about the real opportunity it now presents. He explained that the capital raised in the past 18 months, coupled with new long-term investors, positions MGC Pharma to build a sustainable future, providing returns to shareholders who faced dilution. Looking ahead to 2024, Zomer outlined key initiatives in the company's work plan. The focus will be on completing studies on CimetrA, a drug with potential applications, to enable submission to the FDA for an Investigational New Drug (IND) designation. Simultaneously, ongoing clinical trials will pave the way for seeking early access schemes in the United States and eventually obtaining marketing authorization globally. The second drug, CannEpil, designed for drug-resistant epilepsy, will also undergo enrolment and IND submission, with efforts split evenly between both drugs. Zomer highlights the commercial focus on CannEpil in the UK and Ireland, but says CimetrA takes precedence in terms of IND submission, with both drugs considered essential for the company's progress. As the pharmaceutical landscape evolves, Zomer anticipates increased sales of CimetrA through existing schemes, additional purchase orders, and revenue growth. By mid-2024, Zomer envisions CimetrA entering the IND process, with results from dose-finding studies and the initiation of the IND submission for CanAppeal. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 14, 2023 12:57 PM Eastern Standard Time

Video

Health History on the Menu: This Thanksgiving Pass the Pumpkin Pie--and Grandma’s Health History

YourUpdateTV

Thanksgiving is a day filled with food, football, and conversations with family. While loved ones spend time together safely this Thanksgiving, they should consider talking about family health history. Recently, Susan Manley, senior vice president of Medical Services at Myriad Genetics and Ashley Dedmon, breast cancer previvor conducted a satellite media tour to talk about the importance of initiating health conversations at your holiday gathering. A video accompanying this announcement is available at: https://youtu.be/j0VMnkq1ij4 More than half (55%) of respondents to a recent Myriad Genetics Cancer Risk survey of women said that it’s important to know their cancer risk for “peace of mind.” Yet, 20% of women say they don’t talk about health issues in their family. This has potentially life-threatening consequences. Patients with a family history of breast, ovarian, uterine, or colorectal cancer may have a higher risk for developing these cancers. Getting answers to these questions may qualify your viewers for genetic hereditary cancer testing, which can help people and their clinician determine if they are at an increased risk of developing specific types of cancer. November is Family Health History Month. Encourage your audience to talk about family health history – it may save some lives. Myriad Genetics has an easy-to-complete family health history form to help start the conversation and take notes. During the holiday season, people can bring this form along to family gatherings and complete it by asking as many blood relatives, parents and grandparents, aunts and uncles, sisters and brothers about their family history. To learn more visit: myriad.com/KNOWYOURHISTORY BIOS Susan Manley, MS, MBA Senior Vice President, Medical Services Myriad Genetics, Inc. Salt Lake City, Utah Susan received her undergraduate degree in Biological Sciences from the University of Wisconsin-Milwaukee with a certification in biotechnology, her Master’s degree in Genetic Counseling from the University of Cincinnati, and her MBA from Loyola University in Maryland. She is an American Board of Genetic Counseling certified Genetic Counselor and holds a Genetic Counselor license in the state of Utah. She has been employed at Myriad Genetics for the past 28 years in both medical support and commercialization capacities and has been involved in the development of the commercial genetic testing market from medical, ethical, clinical, counseling, sales and marketing standpoints. Currently, she oversees a large staff of licensed genetic counselors who provide professional customer support and patient education for Myriad’s hereditary cancer and prenatal products. She is published in the medical literature including JAMA, JCO and Breast Cancer Research and Treatment. This combination of clinical knowledge and commercialization experience is unique and valuable in precision medicine space. Ashley Dedmon Breast cancer has impacted Ashley Demon’s family since before she was born - three generations of women in her family have been impacted by this disease. Ashley’s great grandmother, grandmother and mother all passed away from breast cancer, Ashley’s mother at only 42, when Ashley was 21. Cancer didn't stop there: her father was diagnosed with prostate cancer. Ashley’s hereditary mutations heightened her cancer risk. After taking the MyRisk® Hereditary Cancer Test, she learned she carried the BRCA2 gene mutation, putting her at an elevated risk for breast, ovarian and other cancers. After her first daughter had successfully weaned from breastfeeding, Ashley consulted with her doctors and came to the decision to have a prophylactic mastectomy, a procedure which could significantly reduce her risk of developing breast cancer. Since then, Ashley’s been living a normal life and has since given birth to a second daughter. Ashley’s doctors continue to actively monitor her health. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 14, 2023 10:00 AM Eastern Standard Time

Video

With New Lab/Operations Hub, Cardio Diagnostics Says it’s Prepared To Meet Uptake In Demand, Announces New Partner Initiative

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Nearly 50% of Americans live with diabetes, obesity, hypertension or another major cardiovascular risk, according to the Centers for Disease Control and Prevention (CDC). For many Americans, the first sign of coronary heart disease (CHD) is a heart attack. A recent announcement by Cardio Diagnostics (NASDAQ: CDIO) details a bright future for the company’s AI-driven molecular heart disease tests, which evaluate objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have coronary heart disease. After securing an Innovation Technology contract with Vizient, Inc. — the nation’s largest provider-driven healthcare performance improvement company — Cardio Diagnostics will have access to a potential customer base that encompasses greater than 60% of hospitals and 97% of academic medical centers in the United States. On the flip side, Vizient provider customers will have access to Cardio Diagnostics' state-of-the-art tests at negotiated pricing, thereby increasing access to the next generation of cardiovascular disease detection technology. The contract, effective Nov. 1, signifies to Vizient hospital and health system customers a shift toward unique technology that has the potential to bring improvement and cost savings to the healthcare industry. Vizient’s diverse customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers. The company represents more than $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with customer-led councils and task forces to review potentially innovative products. This new contract with Cardio Diagnostics demonstrates Vizient’s confidence in the company’s Epi+Gen CHD and PrecisionCHD tests, which utilize proprietary laboratory assays and AI-driven algorithms to analyze objective epigenetic and genetic biomarkers from a patient's blood sample. Scaling The Business Based in part on the new contract with Vizient and what it believes to be increasing interest in its epigenetic tests, Cardio Diagnostics is preparing to fulfill demand while keeping costs down through the launch of a new facility. Last month, Cardio Diagnostics announced the launch of a new integrated facility in Iowa City, Iowa, that will house a research laboratory, high-complexity Clinical Laboratory Improvement Amendments (CLIA) laboratory and fulfillment center. The new hub will work as the epicenter for distributing sample collection kits to clients and performing all laboratory research and commercial testing. With a modular setup, the high-complexity CLIA laboratory will enable Cardio Diagnostics to process up to 10,000 tests per month while reducing laboratory processing costs by up to 60%. Those fees currently account for the largest portion of the cost of goods sold. Cardio Diagnostics reports that performing kitting and fulfillment of sample collection kits internally further reduces this cost by up to 56%. By integrating operations in-house, Cardio Diagnostics expects to meaningfully improve its gross profit margin while continuing to explore opportunities to further scale capacity and drive down costs. In addition to its pioneering Epi+Gen CHD and PrecisionCHD tests, Cardio Diagnostics is expanding its diagnostic portfolio, by developing tests for stroke, diabetes and heart failure at this new facility. This horizontal integration approach broadens the company's market reach, catering to a more comprehensive range of cardiovascular diseases across the care continuum. By accelerating the development of its product portfolio, Cardio Diagnostics not only enhances its market positioning but also aligns with the trend towards comprehensive, multi-faceted diagnostic solutions in healthcare. Initial operations at this facility are expected to commence in Q4 2023, with full operations anticipated in Q1 2024. "Establishing an internal high-complexity CLIA lab will facilitate the development of a testing process that can be completed in under four hours,” said Robert Philibert, MD Ph.D., Cardio Diagnostics’ Chief Medical Officer. “This time frame fits well with our vision of our heart disease diagnostic tests being eventually offered as essentially point-of-care tests, with a same-day turnaround in almost all medical markets.” With the Vizient contract in place, demand for Cardio Diagnostics tests will soon be higher than ever before. The launch of Cardio Diagnostics’ operational hub will increase distribution and sample processing capabilities, helping the company fulfill demand while fostering continued innovation and setting new standards to improve patient outcomes globally through low-cost precision cardiovascular diagnostics. This progress will assist in furthering detection for the many individuals at risk for and impacted by cardiovascular disease. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website http://www.cardiodiagnosticsinc.com/

November 14, 2023 09:25 AM Eastern Standard Time

1 ... 76 77 78 79 80 ... 309